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INTRODUCTION
Axillary lymph node dissection (ALND), along with 
mastectomy, has played an important role in the radical 
treatment and staging of breast cancer since it was introduced 
by Halstead [1,2]. However, there is a risk of complications such 
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Purpose: Sentinel lymph node biopsy (SLNB) is the standard axillary procedure in early breast cancer patients. In a 
randomized trial, the survival rates were not different when axillary lymph node dissection (ALND) was omitted in patients 
with 1 or 2 lymph node metastases who underwent breast conserving surgery. This study aimed to compare the outcomes 
in patients who underwent total mastectomy (TM) with 1 or 2 metastatic nodes according to the types of axillary surgery.
Methods: In total, 79,058 patients registered in the Korean Breast Cancer Society database who underwent TM were 
included in the analysis. The inclusion criteria were history of TM and SLNB, pathologic T stage 1 or 2, clinically negative 
axillary lymph nodes, 1 or 2 metastatic axillary lymph nodes, no radiation therapy, and no neoadjuvant therapy. We 
divided the patients into the SLNB only and SLNB + ALND groups. The groups were matched by propensity scores. We 
retrospectively analyzed the differences in the overall survival (OS) between the 2 groups.
Results: A total of 883 patients were matched in a 1:4 ratio for the SLNB only and SLNB + ALND groups in the cohort from 
1999 to 2014. There were no significant differences in OS between the 2 groups (P = 0.413). Subgroup analysis revealed a 
significant survival benefit in the SLNB + ALND group in the T2 subgroup (P = 0.013).
Conclusion: OS did not differ between the 2 groups in early breast cancer patients with 1 or 2 metastatic axillary lymph 
nodes who underwent TM. Omission of ALND may be considered in selected patients.
[Ann Surg Treat Res 2020;98(6):283-290]
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as lymphedema and axillary nerve damage, which can lead to 
poor quality of life [3-5].
Sentinel lymph node biopsy (SLNB) is considered a standard 
procedure for histologically identifying axillary lymph node 
metastasis in clinically node-negative breast cancer. With the 
introduction of SLNB, the number of ALNDs has decreased 
compared to that in the past. Furthermore, several clinical 
trials have been conducted on procedures that can be used 
to omit ALND even in SLNB with 1 or 2 axillary lymph node 
metastases [6-8]. The American College of Surgeons Oncology 
Group (ACOSOG) Z0011, a randomized trial, reported that there 
was no effect on the survival rate after omission of ALND for 1 
or 2 lymph node metastases identified in SLNB in early breast 
cancer patients who underwent breast conservative surgery 
(BCS) [9]. In addition, as breast screening examination increases 
the early detection of breast cancer, the number of early breast 
cancer patients has increased [10,11].
Although BCS is mostly performed in patients with early 
breast cancer, total mastectomy (TM) may be inevitable 
depending on various factors such as tumor location. 
Furthermore, the rate of mastectomy has increased again since 
2013. This is because advances in imaging diagnosis such as 
magnetic resonance imaging have made it easier to diagnose a 
wide range of breast cancer and multiple breast cancers, and the 
National Health Insurance Service covers breast reconstruction 
for breast cancer and actively reflects patients’ opinions on 
fear of recurrence or expectations of improved survival [12-14]. 
However, although several studies have suggested that radiation 
therapy, usually involved in BCS, may have a therapeutic effect 
on residual lymph nodes [15,16], lymph node metastasis in 
patients undergoing TM without radiotherapy has rarely been 
studied with SLNB alone. We used data from the Korean Breast 
Cancer Society registration system (KBCR) to evaluate the 
usefulness of ALND in patients with early breast cancer who 




This study enrolled patients older than 18 years with early 
breast cancer who underwent TM. The large-scale data of the 
KBCR were retrospectively analyzed. Since 1996, the KBCR 
has collected data from 110 training hospitals nationwide in 
Korea. The cause and date of death in these data were used in 
connection with the data of the Korea Central Cancer Registry 
(Ministry of Health and Welfare in collaboration with the 
Korean National Statistical Office) to compile complete death 
statistics which were updated through 2014. The study was 
approved by the Institutional Review Board of Daejeon St. 
Mary’s Hospital (No. DC18RESI0041). The inclusion criteria 
were: TM and SLNB, pathologic T stage 1 or 2, clinically negative 
axillary lymph nodes, 1 or 2 positive axillary lymph nodes 
on final pathology, no radiation therapy, and no neoadjuvant 
therapy.
The basic clinical characteristics of patients assessed include 
327 Exclusion after matching
*Matched factors:
*SLNB: SLNB + ALND
Age, T stage, ER/PR, HER2, histology grade, nuclear grade, LVI
= 1:4
77,848 Exclusion
*pT0, Tis, T3, T4 and unknown T stage: 16,731
*Clinical metastatic axillary lymph mode: 11,207
*Metastatic lymph node(-) or lymph node(+) > 3: 42,377
*Radiotherapy: 1,106
*Neoadjuvant/palliative chemotherapy or hormonal therapy: 176
*No axillary surgery: 185
*Unknown or error mortality date: 441
*Unknown ER/PR, HER2, histology or nuclear grade, LVI: 3,758
*Primary ALND: 1,146
*Missing data from other analyzed factors: 721
Clinical data of 79,058 patients diagnosed
breast cancer who underwent TM
1,210 Patients were included





Fig. 1. Selection and matching 
of patients who underwent total 
mastectomy (TM). ER, estrogen 
receptor; PR, progesterone recep­
tor; HER2, human epidermal 
growth receptor 2; LVI, lympho­
vascular invasion; ALND, axillary 
lymph node dissection; SLNB, 
sentinel lymph node biopsy.
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axillary operation method, age, pathologic T stage, lymph node 
status, immunohistochemistry, histologic type, histologic grade, 
nuclear grade, lymphovascular invasion, number of metastatic 
lymph nodes, total number of lymph nodes, family history, 
menopausal status, position of tumor, adjuvant chemotherapy 
or hormonal therapy, and overall survival (OS).
As 2 groups for analysis, the SLNB only and SLNB + ALND 
groups were matched according to the maximum propensity 
scores (1:4). The factors matched included age, pathologic T 
stage, estrogen receptor or progesterone receptor status, human 
epidermal growth receptor 2 status, histologic grade, nuclear 
grade, and lymphovascular invasion. The primary endpoint 
was a comparison of the OS differences between the 2 groups. 
In addition, a subgroup analysis was performed to confirm the 
OS according to the axillary operation method for each clinical 
factor.
Study population
A total of 79,058 patients who underwent mastectomy were 
excluded as they did not meet the inclusion criteria or had 
insufficient data. The remaining 1,210 patients were matched 
by propensity scores using the matched factors, and a total of 
883 patients were included in the analysis (Fig. 1). In addition, 
we compared the annual incidences of the SLNB only and 
SLNB + ALND groups among patients who met the diagnostic 
inclusion criteria: pathologic T stage 1 or 2, clinically negative 
axillary lymph nodes, and 1 or 2 metastatic axillary lymph 
nodes in the final pathology.
Statistical analysis
The clinical characteristics of patients in the matched cohort 
were compared using the chi-square test and the Student t-test. 
The differences in survival between the 2 groups were assessed 
via multivariate logistic regression analysis, the Kaplan-Meier 
method, and Cox proportional hazards regression analysis. 
Subgroup analysis, according to clinical factors, was used to 
identify factors that yielded differences in survival according to 
additional ALND. All statistical analyses were performed using 
IBM SPSS Statistics ver. 22.0 (IBM Co., Armonk, NY, USA), and 
P-value <0.05 was considered sta tistically significant.
RESULTS
Annual incidence of SLNB only or SLNB + ALND 
among patients who underwent TM with 1 or 2 
metastatic axillary lymph nodes
Of the 79,058 patients who underwent TM, 3,632 patients 
were met the diagnostic inclusion criteria. The numbers of 
performed SLNB only and SLNB + ALND have increased 
respectively and the proportion of only received SLNB also has 
increased from 1999 to 2015 (Fig. 2).
Clinical characteristics
Among the 883 patients in the matched cohort from 1999 to 
2014, the median follow-up period was 54.00 ± 36.946 months. 
Apart from the histologic type (P = 0.019), number of metastatic 
lymph nodes (P < 0.001), total number of lymph nodes (P < 
0.001), and chemotherapy (P < 0.001), there were no significant 
differences in the other characteristics between the 2 groups 
(Table 1).
Factors associated with axillary dissection and 
survival
Multivariate logistic regression of factors apart from those 
matched revealed that ALND was more frequent among patients 
with 2 metastatic lymph nodes, invasive ductal carcinoma, and 
chemotherapy (Table 2) and that hormonal therapy significantly 
improved the OS (Table 3).
Kaplan-Meier survival analysis revealed no difference in OS 
between the SLNB only and SLNB + ALND groups (P = 0.396) 
(Fig. 3).
The Cox proportional hazards model revealed no difference 
in OS between the SLNB only and SLNB + ALND groups (hazard 
ratio [HR], 0.728; P = 0.413). Only hormonal therapy showed a 









































Fig. 2. Annual incidence of 
axillary operation in the patients 
who met the diagnostic inclusion 
criteria. SLNB, sentinel lymph 
node biopsy; ALND, axillary 
lymph node dissection.
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Table 1. Clinical characteristics of axillary sentinel lymph node biopsy and additional axillary lymph node dissection
Characteristic SLNB only (n = 179, 20.3%) SLNB + ALND (n = 704, 79.7%) P­value
Age (yr) 50.78 ± 12.34 50.81 ± 11.44 0.972
   <50 105 (58.7) 413 (58.7) 0.999
   ≥50 74 (41.3) 291 (41.3)
T stage
   T1 83 (46.4) 326 (46.3) 0.988
   T2 96 (53.6) 378 (53.7)
ER or PR
   No 27 (15.1) 104 (14.8) 0.917
   Yes 152 (84.9) 600 (85.2)
HER2
   No 137 (76.5) 545 (77.4) 0.802
   Yes 42 (23.5) 159 (22.6)
Histologic type
   IDC 160 (89.4) 668 (94.9) 0.019
   ILC 14 (7.8) 29 (4.1)
   Others 5 (2.8) 7 (1.0)
Histology grade
   G1–2 130 (72.6) 515 (73.2) 0.887
   G3 49 (27.4) 189 (26.8)
Nuclear grade
   G1–2 126 (70.4) 501 (71.2) 0.839
   G3 53 (29.6) 203 (28.8)
Lymphovascular invasion
   No 101 (56.4) 400 (56.8) 0.924
   Yes 78 (43.6) 304 (43.2)
No. of metastatic lymph nodes
   1 159 (88.8) 476 (67.6) <0.001
   2 20 (11.2) 288 (32.4)
Total No. of lymph nodes 6.72 ± 5.70 16.16 ± 7.50 <0.001
Family history
   No 162 (90.5) 642 (91.2) 0.773
   Yes 17 (9.5) 62 (8.8)
Menopause
   No 105 (58.7) 399 (56.7) 0.632
   Yes 74 (41.3) 305 (43.3)
Position of tumor
   Inner 37 (20.7) 157 (22.3) 0.319
   Outer 116 (64.8) 416 (59.1)
   Central 26 (14.5) 131 (18.6)
Chemotherapy
   No 43 (24.0) 66 (9.4) <0.001
   Yes 136 (76.0) 638 (90.6)
Hormonal therapy
   No 34 (19.0) 127 (18.0) 0.768
   Yes 145 (81.0) 577 (82.0)
Overall survival
   No 171 (95.5) 646 (91.8) 0.087
   Yes 8 (4.5) 58 (8.2)
Values are presented as mean ± standard deviation or number (%).
SLNB, axillary sentinel lymph node biopsy; ALND, axillary lymph node dissection; ER, estrogen receptor; PR, progesterone receptor; 
HER2, human epidermal growth receptor 2; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.
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significant survival benefit (HR, 0.337; P < 0.001) (Table 4).
Subgroup analysis
In the subgroup analysis, SLNB + ALND among patients in the 
stage T2 group showed survival benefits when assessed via Cox 
proportional hazards model divided by immunohistochemistry, 
age, T stage, number of metastatic lymph nodes, and histologic 
type (HR, 0.356; P = 0.013) (Fig. 4).
DISCUSSION
Our study revealed that additional ALND did not affect the 
survival rate among early breast cancer patients who underwent 
TM and SLNB with 1 or 2 axillary lymph node metastasis in 
the final pathology. In the ACOSOG Z0011, the median follow-
up period among enrolled patients with 1 or 2 pathologically 
identified positive lymph nodes from SLNB was 6.3 years; the 
5-year OS was 92.5% with SLNB and 91.8% with ALND [9]. Our 
study included patients with 1 or 2 metastatic lymph nodes in 
the final pathology, unlike the ACOSOG Z0011. The median 
follow-up period was 4.5 years, and the 5-year OS was 88.8% 
with SLNB and 93.6% with ALND. Similar to the present study, 
Lee et al. [17] reported that there was no difference in OS 
regardless of ALND among patients with early breast cancer 
who underwent BCS with 1 or 2 positive lymph nodes in the 
final pathology. FitzSullivan et al. [18] reported that there was 
no significant difference in recurrence-free survival and OS 
among patients with metastatic lymph nodes from TM and 
Table 2. Multivariate analysis for clinical factors associated 
with axillary operation
Characteristic OR 95% CI P­value
No. of metastatic lymph nodes
   1 1.000 ­
   2 3.445 2.094–5.668 <0.001
Family history
   No 1.000 ­
   Yes 0.922 0.512–1.662 0.788
Menopause
   No 1.000 ­
   Yes 1.265 0.886–1.806 0.196
Position of tumor
   Inner 1.000 ­
   Outer 0.845 0.550–1.299 0.443
   Central 1.160 0.654–2.056 0.612
Histologic type
   IDC 1.000
   ILC 0.500 0.251–0.997 0.049
   Others 0.582 0.174–1.951 0.381
Chemotherapy
   No 1.000 ­
   Yes 2.770 1.772–4.331 <0.001
Hormonal therapy
   No 1.000 ­
   Yes 1.134 0.730–1.762 0.575
OR, odds ratio; CI, confidence interval; IDC, invasive ductal 
carcinoma; ILC, invasive lobular carcinoma.
Table 3. Clinical factors associated with overall survival
Characteristic OR 95% CI P­value
Axillary operation
   SLNB only 1.000 ­
   SLNB + ALND 2.045 0.920–4.546 0.079
No. of metastatic lymph nodes
   1 1.000 ­
   2 1.223 0.702–2.129 0.477
Family history
   No 1.000 ­
   Yes 0.760 0.291–1.985 0.575
Menopause
   No 1.000 ­
   Yes 0.734 0.427–1.260 0.262
Position of tumor
   Inner 1.000 ­
   Outer 1.258 0.634–2.496 0.511
   Central 2.184 0.990–4.817 0.053
Histologic type
   IDC 1.000
   ILC 1.611 0.544–4.771 0.389
   Others <0.001 ­ 0.999
Chemotherapy
   No 1.000 ­
   Yes 0.657 0.301–1.437 0.293
Hormonal therapy
   No 1.000 ­
   Yes 0.297 0.170–0.520 <0.001
OR, odds ratio; CI, confidence interval; SLNB, axillary sentinel 
lymph node biopsy; ALND, axillary lymph node dissection; IDC, 
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Fig. 3. Survival curves of SLNB group and SLNB + ALND 
group. SLNB, sentinel lymph node biopsy; ALND, axillary 
lymph node dissection.
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SLNB regardless of additional ALND or irradiation. In this 
regard, the omission of ALND may be expected to reduce 
morbidity and improve the quality of life among early breast 
cancer patients who underwent TM and SLNB with 1 or 2 
axillary lymph node metastasis.
In this study, there were some cases where ALND was 
omitted prior to the announcement of the ACOSOG Z0011 
results. Since the design of our study is retrospective, we were 
not able to determine the exact reason why ALND was omitted 
on such cases. However, given that there were several studies 
prior to 2011 on the omission of ALND in breast cancer patients 
with favorable features [19,20], we presumed that those studies 
provided basis for ALND omission.
There was no difference in adjuvant chemotherapy rates 
between the SLNB and ALND groups in ACOSOG Z0011. 
However, in our study, the adjuvant chemotherapy rate was 
relatively higher in the SLNB + ALND group (90.6%) than in 
the SLNB only group (76.0%) (P < 0.001). Considering that 
27.3% of patients had nonsentinel lymph node metastasis in 
ACOSOG Z0011 [21], although there is a possibility that some 
metastatic lymph nodes remain and the relatively low adjuvant 
chemotherapy rates in the SLNB only group of our study, the 
lack of difference in survival seems to be a meaningful result.
The survival rate was higher among patients who received 
hormonal therapy than among those who did not. This seems 
to be in the same context that, as is known, patients with 
hormone receptor positive disease showed a better survival rate 
than did those with hormone receptor negative disease [22-25].
The most common histologic type in this study was invasive 
ductal carcinoma, and invasive lobular carcinoma was rare 
(4.9%). The proportion of patients with invasive lobular 
carcinoma was relatively high in the SLNB only group, but there 
was no difference in survival rate according to histologic type. 
In some studies, ALND was not related to survival in invasive 
lobular carcinoma meeting the ACOSOG Z0011 criteria [26,27].
In the subgroup analysis, unlike the T1 subgroup, additional 
ALND resulted in a significantly higher survival benefit than 
SLNB only in the T2 subgroup. Considering that nonsentinel 
lymph node metastasis was related to tumor size in other 
studies [28,29], even if it is included in the category of early 
Table 4. Prognostic factors of overall survival
Characteristic HR 95% CI P­value
Axillary operation
   SLNB only 1.000 ­
   SLNB + ALND 0.728 0.340–1.557 0.413
No. of metastatic lymph nodes
   1 1.000 ­
   2 1.228 0.728–2.071 0.442
Family history
   No 1.000 ­
   Yes 0.774 0.305–1.964 0.589
Menopause
   No 1.000 ­
   Yes 0.743 0.439–1.259 0.270
Position of tumor
   Inner 1.000 ­
   Outer 1.244 0.645–2.400 0.515
   Central 1.541 0.731–3.248 0.256
Histologic type
   IDC 1.000
   ILC 1.807 0.641–5.095 0.263
   Others <0.001 ­ 0.969
Chemotherapy
   No 1.000 ­
   Yes 0.505 0.239–1.066 0.073
Hormonal therapy
   No 1.000 ­
   Yes 0.337 0.200–0.568 <0.001
HR, hazard ratio; CI, confidence interval; SLNB, axillary sentinel 
lymph node biopsy; ALND, axillary lymph node dissection; IDC, 
invasive ductal carcinoma; ILC, invasive lobular carcinoma.
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Fig. 4. Subgroup analysis of 
clinical factors affecting overall 
survivals of axillary operation. 
HR, hazard ratio; CI, confidence 
interval; ER, estrogen receptor; 
PR, progesterone receptor; 
HER2, human epidermal growth 
receptor 2; LN, lymph node; 
IDC, invasive ductal carcinoma; 
SLNB, sentinel lymph node 
biopsy; ALND, axillary lymph 
node dissection.
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breast cancer, it is necessary to subdivide it to consider 
additional ALND.
In ACOSOG Z0011, tangential field whole breast irradiation 
was performed after BCS in all patients, which partially 
included or did not include the axillary field [15,16]. 
Radiotherapy as adjuvant therapy was the main target of 
residual breast tissue after BCS. Axillary irradiation may have 
been secondarily included in the tangential field according to 
the radiologist’s findings, but this was not the main adjuvant 
therapy. In this study, TM itself was not an indication for 
tangential field whole breast irradiation. In AMAROS trial, there 
was no difference in survival between the ALND group and the 
axillary radiotherapy group in early breast cancer patients with 
sentinel lymph node metastasis [30]. On this basis, adjuvant 
radiotherapy after TM was excluded to rule out the effects of 
adjuvant therapy in the axillary field.
The main strengths of this study were that we reduced 
confounders via propensity score matching and increased 
the reliability by assessing more homogenous populations. 
However, this study has several limitations. First, it was a 
retrospective study. Additionally, limited information was 
available on prognosis, such as recurrence or breast cancer 
specific survival. Then, prognosis was assessed using OS. 
However, there was a possibility that other factors might have 
been involved in mortality. Furthermore, in the SLNB + ALND 
group, the total and metastatic lymph nodes were registered 
as the mixture of data regarding sentinel lymph nodes and 
additional dissected lymph nodes, which limited their further 
analysis. Most of the analysis data contained data from 2010 
onwards, so the follow-up period was rather short. Finally, the 
matched factors were mainly the pathological factors of breast 
cancer, and there is a possibility that the analysis result might 
be influenced by selection bias of other unmatched factors.
In this study, we confirmed that there was no difference in 
the patients’ survival rate regardless of additional ALND even 
among early breast cancer patients who underwent TM and 
SLNB with 1 or 2 axillary lymph node metastases in the final 
pathology. Although further studies are needed, omission of 
ALND may be considered in selected patients.
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